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Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90 S79median age of 16 (2-80) months at transplantation with a
median follow-up of 8.9 (3-22.6) years after last HCT. Post-
transplant leukocyte IDUA enzyme levels below the lower
reference were seen in 25% of patients due to mixed-
chimerism or the use of a carrier donor. Following successful
HCT, the clinical course of HS patients is strikingly improved,
evident in all organ systems. Residual disease burden is
present in the majority of the patients with high variability
between patients. A better cognitive status at HCT was a
major predictor for superior cognitive development after
HCT (ﬁgure 1). Signiﬁcant predictors for superior long-term
outcome in all organ systems were the presence of “normal
IDUA enzyme levels obtained after HCT” and a “younger
age at transplantation”. See the association between the
leukocyte IDUA enzyme level obtained after HCTand surgical
intervention for cord compression and growth, in ﬁgure 2
and 3 respectively.
Conclusion: Although HCT signiﬁcantly improved the
clinical course in HS patients, residual disease burden was
observed in the majority of transplanted HS patients.
Using exclusively non-carrier donors and accepting only
full donor-chimerism will improve the prognosis of
HS patients. Reducing the age at HCT through newborn
screening could further improve the outcomes of HS pa-
tients after HCT.83
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Allogeneic stem cell transplantation (alloSCT) remains the
only curative option for sickle cell disease (SCD). However, no
systematic analysis exists comparing cost and quality of life
(QOL) among this population. We investigated the QOL
outcomes and health care utilization associated with alloSCT
in children with SCD.
Internal ﬁnancial data from 2002-2011 was analyzed retro-
spectively across two groups e post-alloSCT patients
(>day+365) and patients with SCD referred for alloSCT and/
or HLA typed. Surviving alloSCT recipients (A) and SCD
controls (B) were surveyed with age appropriate Pediatric
Quality of Life Inventory (PedsQLa) and EuroQOL (EQ-5Da)Post-AlloSCT
(>D+365, group A)
Controls
(group B)
p-value
Mean outpatient visits 0.93 1.81 <0.0001
Mean outpatient cost ($) 831.10 739.2 0.840
Mean outpatient cost
per QOL ($/QALM)
723.67 442.16 0.3506
Mean inpatient visits 0.02 0.52 <0.0001
Length of stay 0.06 1.05 <0.0001
Mean inpatient cost ($) 293.80 2050.20 0.115
Mean inpatient cost
per QOL ($/QALM)
345.69 769.08 0.0023questionnaires. Group A siblings without SCD (C) were also
surveyed as unaffected controls. Mean QOL scores were
calculated for each group with a max score of 100. Utility
scores were determined based on EQ-5D responses. These
scores and costs for groups A and B were used to calculate
cost per quality adjusted life month (QALM) for the cohort of
patients surveyed. Wilcoxon test was used to determine
statistical signiﬁcance.
Group A, B, and C had 16 (mean age - 14yrs), 19 (mean age -
12yrs), and 14 children (mean age - 14yrs), respectively. SCD
therapy included hydroxyurea (group A n¼8, group B n¼10)
and chronic transfusions (group A n¼7, group B n¼2). Mean
PedsQL scaled scores were 83, 81, and 88, respectively. Mean
EQ-5D visual analogue scale scores were 92, 87, 96, respec-
tively. Mean utility scores were 0.87, 0.91, and 0.89, respec-
tively. All QOL scores were not statistically signiﬁcant (p ¼
0.2638). Healthcare utilization among groups A and B was
previously reported (see details in table below). The median
inpatient cost per QALM for group A was $0 and $514 for
group B (p ¼ 0.0023). Outpatient cost per QALM for group A
was $353 and $236 for group B (p ¼ 0.3506).
SCD patients’ post-alloSCT QOL scores are similar to unaf-
fected siblings, indicating that QOL has normalized. Controls
with SCD also had scores similar to unaffected controls.
However, a statistically signiﬁcant difference exists in the
inpatient cost per QALM post-alloSCT compared to controls
with SCD. Outpatient was not signiﬁcant which may reﬂect
the limitations of the study period as post-alloSCT QOL and
cost can change over time (Felder-Puig 2006; Majhail 2010).
Ultimately, this study provides the ﬁrst combined analysis of
QOL as an outcome and the economic impact of alloSCT for
pediatric SCD patients. Further analysis is ongoing to afﬁrm
that alloSCT is a beneﬁcial and cost effective management
option for patients.84
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Background: Children, adolescents, and young adults
(CAYA) with Acute Leukemia in third complete remission
Figure 1. TMA trend in pediatric HSCT recipients
Figure 2
Demographics, risk factors and outcome of patients with TMA
Variable Overall No TMA TMA p
12369 12276 93
Age 0 e 1 years 1948 (15.7) 1939 (99.5) 9 (0.5) 0.109
2 e 4 years 2819 (22.8) 2793 (99.1) 26 (0.9)
5 e 9 years 2775 (22.4) 2758 (99.4) 17 (0.6)
10 e 14
years
2339 (18.9) 2314 (98.9) 25 (l.1)
 15 years 2488 (20.1) 2472 (99.4) 16 (0.6)
Sex Male 7239 (58.5) 7187 (99.3) 52 (0.7) 0.608
Female 5130 (41.5) 5089 (99.2) 41 (0.8)
Race Non-
Hispanic
White
6974 (56.4) 6914 (99.1) 60 (0.9) 0.265
Non-
Hispanic
Black
1450 (11.7) 1445 (99.7) 5 (0.3)
Hispanic 2304 (18.6) 2290 (99.4) 14 (0.6)
Asian 432 (3.5) 428 (99.1) 4 (0.9)
Other 1209 (9.8) 1199 (99.2) 10 (0.8)
Other 7560 (61.1) 7494 (99.1) 66 (0.9)
HSCT Type Autologous 4043 (32.7) 4031 (32.8) 12 (12.9) <.001
Allogeneic 8177 (66.1) 8099 (66) 78 (83.9)
Not speciﬁed 149 (1.2) 146 (1.2) 3 (3.2)
Allo Source Bone
Marrow
3517 (43) 3492 (43.1) 25 (32.1) 0.045
Peripheral
blood
3195 (39) 3154 (38.9) 41 (52.6)
Cord blood 1475 (18) 1463 (18) 12 (15.4)
CMV 958 (7.7) 940 (7.7) 18 (19.4) <.001
HHV6 138 (1.1) 130 (1.1) 8 (8.6) <.001
Fungal
infection
835 (6.8) 814 (6.6) 21 (22.6) <.001
GVHD 1471 (11.9) 1443 (11.8) 28 (30.1) <.001
VOD 227 (1.8) 222 (1.8) 5 (5.4) 0.011
Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90S80(CR3), induction failure (IF) or refractory relapse (RR) have
a poor prognosis. (Gaynon, BJH 2005, Wells, JCO 2003,
Hochster/Cairo, BJH 2013) Clofarabine (CLO), a purine anti-
metabolite, has been shown to have synergy with cytarabine
(Faderl, Blood 2005) and induce lasting remissions following
CLO and busulfan-based conditioning and allogeneic he-
matopoietic cell transplantation (AlloHCT) in poor-risk AML.
(Magneau, Blood 2011).
Objectives: This study seeks to determine the safety, day-
100 treatment-related mortality (TRM), and relapse rate
associated with a conditioning regimen of CLO, cytarabine,
and Total Body Irradiation (TBI) followed by AlloHCT in CAYA
with poor-risk ALL or AML.
Methods: This is a multi-center Phase I/II trial of a novel
conditioning regiment of CLO (maximal dose 52mg/m2/
d achieved without dose limiting toxicity) x5d, cytarabine
1000 mg/m2 x6d 4 hours post-CLO, and TBI (1200cGy)
followed by AlloHCT from matched related or unrelated
donors in CAYA with ALL or AML in CR3, RR or IF. GVHD
prophylaxis consisted of tacrolimus and MMF. (Oswunko/
Cairo, BBMT 2004, Bhatia/Cairo, BBMT 2010) Supportive
care consisted of growth factor support, and CMV and
fungal prophylaxis as previously described. (Waxman/
Cairo, Ped. Transplantation 2009, Shereck/Cairo, Ped. Blood
Cancer 2007, Roman/Cairo, Ped. Blood Cancer 2008) Donor
chimerism was assessed by semi-quantitative PCR-based
methods as previously described. (Geyer/Cairo, BJH 2011)
The Kaplan-Meier method was used to determine the
probabilities of engraftment, GVHD, TRM, and overall sur-
vival (OS).
Results: 30 patients, median age: 11.9 yrs (range 1.5 e
21.8); M:F 21:9, ALL:AML 27:3 (10 CR3, 3RR, 17 IF), 11
related donors, 19 unrelated donors (11 BM/PBSCs, 8 UCB).
Median TNC and CD34 dose was 4.49x108/kg and 4.2x106/
kg for BM/PBSCs and 4.8x107/kg and 3.4x105/kg for UCB.
Probabilities of neutrophil, platelet engraftment, grade II-
IV aGVHD and chronic GVHD were 100%, 93%, 47%, and
35% respectively. Median Day 100, 180, and 365 whole
blood chimerisms were all 100%. Day 100 TRM was only
6.7%. The probabilities of relapse, 1-yr progression-free
survival and OS were 27% (CI95: 13-52%), 40% (CI95: 23-
57%), and 47% (CI95: 28-63%) respectively in this poor-risk
population.
Conclusions: These preliminary results suggest that this
novel conditioning regimen including CLO dose 52 mg/m2
with Ara-C and TBI followed by AlloHCT is safe and tolerated
in CAYAwith poor-risk ALL or AML. Our results are promising
with respect to a low risk of day 100 TRM and relapse rate in
this poor risk population. This approach should be consid-
ered in better risk CAYA patients with ALL/AML who require
AlloHCT.Hypertension 3288 (26.6) 3226 (26.3) 62 (66.7) <.001
Renal failure 1280 (10.3) 1232 (10) 48 (51.6) <.001
Plasmapheresis 119 (1) 91 (0.7) 28 (30.1) <.001
Hemodialysis 385 (3.1) 363 (3) 22 (23.7) <.001
Died 1531 (12.4) 1503 (12.2) 28 (30.1) <.00185
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Introduction: Thrombotic microangiopathy (TMA) is a
rare but serious complication of hematopoietic stem cell
transplantation (HSCT). Review of literature showsvariable incidence of TMA following HSCT with high
mortality but its true incidence and outcome in the pe-
diatric population is not known. The purpose of our study
is to estimate the incidence, prevalence and analyze the
risk factors and outcome of TMA in children receiving
HSCT.
